• 제목/요약/키워드: Defined Daily Dose

검색결과 20건 처리시간 0.022초

상한론(傷寒論)에서 대조(大棗)의 1 일 복용량 (Daily Dose of Zizyphi Fructus in Treatise on Cold Damage)

  • 김인락
    • 대한본초학회지
    • /
    • 제28권1호
    • /
    • pp.51-58
    • /
    • 2013
  • Objectives : As Daily Dose of Zizyphi Fructus was designated by the numbers in Treatise on Cold Damage Disease, estimation of Daily Dose was all different among researchers. The purpose of this study was to estimate exact Daily Dose of Zizyphi Fructus. Methods : We fixed the errors in various copy of Treatise on Cold Damage Disease and considered the meaning of the Bee Zizyphi Fructus(肥大棗) and general rules of Daily Dose in Treatise on Cold Damage Disease. So we reduced Daily Dose of Zizyphi Fructus, and compared this with the standard of Zizyphy Fructus in Pharmacopoeia of several Nation and Korean Forest Service. Results : Daily Dose of Zizyphi Fructus was generally 12 pieces; less was for prescriptions which scaled down the amount of ingredients prescribed in the originals; 15, 25, and 30 pieces were used when more was required. The medicinal part was the pulp of fructus, and the dosage of 12 pieces was respectively equivalent to 3 Ryang(兩), and 19.5 g. As defined in the Korean Pharmacopoeia Ninth Edition and standards of forest products by Korea Forest Service, Zizyphi Fructus was medium-sized, and weighs about 1.625 g if properly dehydrated. Conclusions : In short, the proper Daily Dose of Zizyphi Fructus in Treatise on Cold damage Disease was 12 pieces of Zizyphi Fructus and 19.5 g of its pulp, weighing three Ryang(兩). The pulp was estimated to be 1.625 g; it was medium-sized according to the present standard.

혈액배양에서 분리된 임상적 주요 균주의 항균제사용량에 따른 내성률 변화 (Antimicrobial resistance rates changes according to the amount of the antimicrobial agent in clinically important strain isolated from blood cultures)

  • 김재중
    • 한국산학기술학회논문지
    • /
    • 제17권5호
    • /
    • pp.653-659
    • /
    • 2016
  • 본 논문의 목적은 항균제 사용량(Defined Daily Dose. DDD)과 세균의 내성률(%)과의 상관성을 보고자 하였다. 항균제 내성은 최근 다제 내성균들의 증가로 인하여 감염증의 치료가 점점 더 어려워져 임상적으로 중대한 문제가 되고 있다. 그리고, 여러 요인들 중에서 항균제 오남용은 항균제 내성의 주요 원인이 되고 있다. 중부권지역의 일개 2차 대학병원의 입원환자를 대상으로 병원전산통계 자료와 진단검사의학과의 미생물 프로그램을 이용하여 2010년 1월부터 2014년 12월 까지 혈액배양에서 분리 동정된 Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli 균주에 대하여 항균제 사용량에 따른 균주의 내성률과의 상관성을 분석하기 위하여 균주 내성률과 항균제 사용량을 각각 조사하였다. 사용량에 따른 항균제 내성률은 pearson상관분석을 실시하였다. 그 결과 cefepime사용량과 cefepime 내성 E. coli에서 유의한 상관관계가 있었고(P<0.033;r=0.907), tobramycin사용량과 tobramycin 내성 E.coli에서도 유의한 음의 상관관계가 있었다(P<0.028;r=-0.917). Aminoglycoside계열 내성 A.baumannii가 유의한 음의 상관관계를 나타냈고(P<0.048;r=-0.881), aminoglycoside계열 내성 E. coli도 유의한 음의 상관관계를 나타냈다(P<0.001;r=-0.992). 결론적으로 항균제 사용량은 일부 세균에서 내성률과 상관성이 있었다.

수정 델파이 기법을 이용한 의약품의 DDD(일일상용량) 결정과 항생제 사용량 분석: WHO 일일상용량이 없는 항생제를 중심으로 (Determination of Defined Daily Dose of Medicines using Nominal Group Technique and Analysis of Antibiotics Use in National Insurance Claim Data: Focused on Antibiotics without DDD of WHO)

  • 김동숙;김남순;이숙향
    • 한국임상약학회지
    • /
    • 제17권1호
    • /
    • pp.19-32
    • /
    • 2007
  • Objectives : It is necessary to monitor consumption of drugs in order to enhance promote appropriate use of drugs. Defined Daily Dose(DDD) of World Health Organization(WHO) has been used for evaluating the amount of medicine use. However, DDD of some drugs must be determined for drugs in Korea which are not listed by WHO. Our formulary follows ourself classification and DDD of some drugs must be determined since they exist only in Korea. This study was aimed to determine DDD value using RAND Appropriateness Methods and evaluate the amount of antibiotics use using DDD value. Methods : J01 antibiotics of WHO anatomical therapeutic chemical(ATC) classification were extracted from drug formulary. Antibiotics list without DDD was identified to determine their DDD with comprehensive review of references and recommendation of experts. defined. Review of reference was executed. of Expert panels were comprised of clinical pharmacist and clinical doctors. Modified Delphi Method was applied by survey and consensus meeting. Amount of antibiotic use was calculated by DDD/1000 inhabitants/day in the national level using health insurance claim data. Results : The result of 1 round, DDD values of 28 ingredients were determined from the first round of consensus meeting. With 2nd round meeting, 3 ingredients were deleted and DDD of 17 ingredients were decided. Analysis of antibiotic use in health insurance claim data showed 22.97 DDD/1000 inhabitants/day in 2003 year. Conclusion : This study can contribute to the establishment of DDD assignment and thus quantifying drug uses.

  • PDF

병원 및 의원급 일일사용량 기준 항생제 사용량에 영향을 미치는 요인 (Analysis of factors affecting antibiotic use at hospitals and clinics based on the defined daily dose)

  • 이은지;이근우;박주희;김동숙;안형식
    • 대한의사협회지
    • /
    • 제61권11호
    • /
    • pp.687-698
    • /
    • 2018
  • Inappropriate antibiotic use significantly contributes to antibiotic resistance, resulting in reduced antibiotic efficacy and an increased burden of disease. The objective of this study was to investigate the characteristics of prescribers whose antibiotics use was high and to explore factors affecting the use of antibiotics by medical institutions. This study analyzed the National Health Insurance claims data from 2015. Antibiotic prescription data were analyzed in terms of the number of defined daily doses per 1,000 patients per day, according to the World Health Organization anatomical-therapeutic-chemical classification and methodologies for measuring the defined daily dose. We investigated the characteristics of prescribers and medical institutions with high antibiotic use. Multivariate regression analyses were performed on the basis of characteristics of the medical institution (number of patients, type of medical institution [hospital or clinic], age of the physician, etc.). The number of patients and number of beds were found to be significant factors affecting antibiotic use in hospitals, and the number of patients, region, and medical department were significant factors affecting antibiotic use at the level of medical institutions. These findings are expected to help policy-makers to better target future interventions to promote prudent antibiotic prescription.

단일 상급종합병원에서 마약성 진통제의 최근 13년간 사용 경향 조사 (Trends in the Consumption of Opioid Analgesics in a Tertiary Care Hospital from 2000 to 2012)

  • 조윤숙;이주연;김향숙;권경희
    • 약학회지
    • /
    • 제58권4호
    • /
    • pp.268-276
    • /
    • 2014
  • Background: World Health Organization considers opioid analgesic use as an important measure in the treatment of pain relief. However, there are limited data about the pattern of opioid analgesic use in tertiary care hospitals in Korea. The aim of this study was to describe the trends in the prescribed amount of the opioid for 13 years from 2000 to 2012 in a single tertiary care hospital. Methods: The data from the prescribed amount of opioid use in patients aged over 18 years were retrieved from medical charts and longitudinal pharmacy records of Seoul National University Hospital. Yearly prescribed amount of opioids were calculated using defined daily dose adjusted by hospital stay (DDD/1000${\bullet}$HS). Results: Over the 13 years of the study period, overall use of opioid has increased by 64.1%. Although, the opioid use by hospitalized patients comprised 98%~99% of total amount of opioid use, the proportions of opioid use by outpatient and by cancer patient increased from 1.1% to 2.2% and from 60.5% to 69.3%, respectively. The use of non-injectable opioids has increased by 47% and that of injectables has increased by 70%. While the amount of codeine and morphine use has decreased, the use of both transdermal and injection formulation of fentanyl has increased dramatically. Also, the use of oxycodone has increased, especially in outpatient setting. Conclusion: This longitudinal study showed that opioid analgesic use in tertiary hospital, especially in outpatient is continuously increasing. Improvement in pain management in tertiary care hospital can be cautiously inferred based on this results.

Utilization of Preventive Therapy in Korean Migraine Patients

  • Kim, Yewon;Park, Susin;Kim, Eonjeong;Je, Nam Kyung
    • 한국임상약학회지
    • /
    • 제31권1호
    • /
    • pp.35-43
    • /
    • 2021
  • Background: Migraine is a common neurological disorder that affects the quality of life and causes several health problems. Preventive migraine treatment can reduce migraine frequency, headache severity, and health care costs. This study aimed to estimate the utilization of migraine preventive therapy and associated factors in eligible patients. Methods: We studied 534 patients with migraine who were eligible for migraine preventive therapy using 2017 National Patient Sample (NPS) data from the Health Insurance Review and Assessment Service (HIRA). We estimated the migraine days by calculating the monthly average number of defined daily dose (DDD) of migraine-specific acute drug. Patients with a monthly average number of DDD of 4 or more were considered as subjects for preventive treatment. Chi-square test and multiple logistic regression analysis were used to determine the association between the preventive therapy and the influencing variables. Results: Less than half of the eligible patients for prophylaxis (n=234, 43.8%) were prescribed preventive therapy. Multiple logistic regression results show that migraine preventive therapy was influenced by age, the type of migraine, and some comorbidities. Patients over the age of 50 tend to receive less prophylactic treatment than under the age of 40. On the other hand, migraine patients with epilepsy or depression were more likely to receive preventive therapy. Sumatriptan was the most preferred medication for acute treatment, and propranolol was the most commonly prescribed drug for prevention. Conclusions: More than half of the patients who were candidates for migraine prophylaxis were not receiving suitable preventive treatment. Positive factors affecting the use of migraine prevention were the presence of comorbidities such as epilepsy and depression.

Fibrinolysis with Lower Dose Urokinase in Patients with Complicated Parapneumonic Effusion

  • Lee, Seul;Lee, Heock;Lee, Dong Hyun;Kang, Bo Hyoung;Roh, Mee Sook;Son, Choohee;Kim, Sung Hyun;Lee, Hyun-Kyung;Um, Soo-Jung
    • Tuberculosis and Respiratory Diseases
    • /
    • 제84권2호
    • /
    • pp.134-139
    • /
    • 2021
  • Background: Intrapleural urokinase is one of the most widely used fibrinolytic agents in the treatment of complicated parapneumonic effusion (CPPE). However, little research has been performed on the optimal urokinase dosage. The aim of this study was to evaluate the treatment efficacy of half dose urokinase compared with conventional dose urokinase. Methods: We retrospectively enrolled 92 patients with CPPE or empyema who underwent intrapleural urokinase treatment at two tertiary hospitals. Patients received antibiotics, chest tube drainage, and other treatments as part of routine care. The primary outcome was the treatment success rate in the half dose urokinase group (50,000 IU daily for maximal 6 days) and the conventional dose urokinase group (100,000 IU daily). Treatment success was defined as clinical and radiological improvements without surgical treatment or re-admission within one month. Results: Forty-four patients received half dose urokinase, whereas 48 patients were treated with conventional dose urokinase. Both groups were relatively well matched at baseline, excluding higher serum white blood cell count and higher empyema prevalence in the half dose urokinase group. The treatment success rate was not different between the two groups (p=0.048). There were no differences in the rate of in-hospital death and surgical treatment, hospitalization duration, and indwelling catheter duration. In the multivariate analysis, urokinase dose was not a predictor of treatment success. Conclusion: Half dose intrapleural urokinase is equally effective conventional dose urokinase in treating patients with CPPE or empyema.

Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study

  • Kim, Dong-Wook;Seo, Won Jun;Youn, Sang Il;Jee, Ye Seob;Jang, You-Jin;Kim, Jong-Han
    • Journal of Gastric Cancer
    • /
    • 제21권4호
    • /
    • pp.418-425
    • /
    • 2021
  • Purpose: We designed a new regimen by combining intraperitoneal (IP) paclitaxel (PTX) with systemic S-1 plus oxaliplatin (SOX) for the treatment of advanced gastric cancer with peritoneal metastasis. This dose-escalation study aimed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of IP PTX administered weekly to patients. Materials and Methods: Eight cycles of IP PTX plus SOX regimen were administered to the patients. S-1 was administered orally twice daily at a dose of 80 mg/m2/day for 14 consecutive days, followed by 7 days of rest. Intravenous oxaliplatin was administered at a fixed dose of 100 mg/m2 on day 1, while IP PTX was administered on days 1 and 8. The initial dose of IP PTX was 40 mg/m2, and the dose escalation was set in units of 20 mg/m2 up to 80 mg/m2. Dose-limiting toxicities (DLTs) were defined as grade 3 non-hematologic toxicities, grade 4 leukopenia, grade 3 febrile neutropenia, and grade 3 thrombocytopenia. Results: Nine patients were included in the study. No DLTs were observed in any of the enrolled patients. Therefore, the MTD was not reached, and the RD of IP PTX was determined to be 80 mg/m2. Four patients (44%) showed a decreased peritoneal cancer index score on second-look laparoscopic examination. Conclusions: The present study determined the dose for further clinical trials of IP PTX to be 80 mg/m2, when combined with a systemic SOX regimen.

한국인의 요오드 섭취와 요오드 상한섭취량 (Iodine Intake and Tolerable Upper Intake Level of Iodine for Koreans)

  • 이현숙;민혜선
    • Journal of Nutrition and Health
    • /
    • 제44권1호
    • /
    • pp.82-91
    • /
    • 2011
  • The present study reviewed the effects of excess iodine intake on thyroid function and the incidence of thyroid disease and discussed the scientific basis for establishing a tolerable upper intake level (UL) of iodine for Koreans. ULs are defined as "the highest level of daily nutrient intake that is likely to pose no risk of adverse effects to almost all individuals in the general population." Koreans consume excess iodine from seaweed, and iodine intake is strongly influenced by seaweed consumption. However, no dose-response data derived from subjects consuming excess iodine frequently but not continuously during a lifetime are available. Therefore, the Korean DRI committee set the iodine UL to reduce the risk of adverse health effects by excess iodine intake for Koreans with distinctive seaweed-eating habits.

1회 2회 분복 투여하는 Moclobemide의 효과와 안전성 : 주요우울장애 환자에서 개방 시험 (The Efficacy and Safety of Moclobemide Twice Daily : An Open Trial in Patients with Major Depressive Disorder)

  • 윤진상;이형영;국승희;최영
    • 생물정신의학
    • /
    • 제3권1호
    • /
    • pp.102-108
    • /
    • 1996
  • 본 연구는 한국인의 우울증 환자에서 moclobemide가 효과적이며 안전하게 사용될 수 있음을 입증하였으며, 투약 방법으로 초기 권장량인 1일 300mg을 2회 분복시키는 방법이 추천될 수 있음을 확인하였다.

  • PDF